Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Gkrepi (Andros, Greece), D. Lowe (London, United Kingdom), S. Burns (London, United Kingdom), S. Seneviratne (London, United Kingdom), J. Hurst (London, United Kingdom). Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD). 1408

Member's Comments

No comment yet.

Related content which might interest you: Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Comparison of Eosinophilic and Non-eosinophilic Cases with Chronic Obstructive Pulmonary Disease (COPD) in terms of Clinical Arrival, Exacerbations, Quality of Life and Response to Treatment: A Prospective Study Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Risk Factor for Chronic Obstructive Pulmonary Disease in Never-Smoker Patients with Non-Cystic Fibrosis Bronchiectasis Source: International Congress 2019 – Bronchiectasis Year: 2019 A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Cognitive failure in sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Study to Evaluate Satisfaction with the Inhalation Device Used by Patients with Asthma or Chronic Obstructive Pulmonary Disease and the Association with Adherence and Disease Control Source: Virtual Congress 2020 – Novel insights into nursing interventions for managing patients with asthma and COPD Year: 2020 The Effects Of Bronchiectasis Severity On Outcomes Of Chronic Obstructive Pulmonary Disease Exacerbation Source: International Congress 2017 – Imaging markers for COPD and asthma Year: 2017 From the Cradle to the Grave - The Early-Life Origins of Chronic Obstructive Pulmonary Disease Source: Virtual Congress 2020 - Pre-reading material Year: 2020 Clinical Features and Treatment Outcome of Carcinomatous Pericarditis due to Lung Cancer. Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome Source: International Congress 2014 – ILDs 1 Year: 2014 Association of Metabolic Syndrome with the severity of Chronic Obstructive Pulmonary Disease Source: Virtual Congress 2020 – Clinical data and COPD management Year: 2020 Low Level of  Airway Mucin 2 Predict Severe Exacerbations in Patients with Severe Chronic Obstructive Pulmonary Disease Source: International Congress 2017 – COPD biomarkers Year: 2017